Cutaneous side effects of inhibition of VEGF signal transduction

Area of Science:

• Oncology
• Molecular Biology
• Dermatology

Background:

• The VEGF signaling pathway is essential for angiogenesis in both normal physiological processes and pathological conditions, particularly in malignant tumors.
• Targeting the VEGF pathway has led to the development of several approved and investigational cancer therapies.
• Current approved therapies include monoclonal antibodies (bevacizumab, ranibizumab) and small-molecule kinase inhibitors (sorafenib, sunitinib).

Purpose of the Study:

• To review the role of the VEGF signaling pathway in angiogenesis and cancer.
• To summarize approved therapies targeting the VEGF pathway.
• To delineate the spectrum of cutaneous side effects associated with these therapies.

Main Methods:

• Literature review of therapies targeting the VEGF signaling pathway.
• Analysis of clinical data regarding the efficacy and side effect profiles of approved drugs.
• Comparison of adverse cutaneous events between different classes of VEGF inhibitors.

Main Results:

• VEGF pathway inhibitors, including monoclonal antibodies and small-molecule kinase inhibitors, are established cancer therapies.
• Bevacizumab elicits less pronounced cutaneous side effects compared to EGF inhibitors, including neuropathy, stomatitis, and dermatitis.
• Small-molecule inhibitors like sorafenib and sunitinib are associated with more frequent and varied skin toxicities, such as pruritic exanthems and hand-foot syndrome.

Conclusions:

• Targeted therapies for the VEGF pathway are vital in oncology.
• Understanding the distinct side effect profiles of monoclonal antibodies versus small-molecule inhibitors is crucial for patient management.
• Managing cutaneous adverse events is essential for maintaining treatment adherence and quality of life in cancer patients.